The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca Spain; Eisai; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pfizer; Pierre Fabre; Roche/Genentech; Tesaro
Travel, Accommodations, Expenses - Celgene; Celgene; Pfizer; Roche
On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.
 
Stephen James Luen
Honoraria - Novartis
Travel, Accommodations, Expenses - Pfizer
 
Gaia Griguolo
Travel, Accommodations, Expenses - Pfizer
 
Paolo Nuciforo
No Relationships to Disclose
 
Christine Campbell
No Relationships to Disclose
 
Roberta Fasani
No Relationships to Disclose
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Daiichi Sankyo; ERYTECH Pharma; Merus; Polyphor; Roche; Seagen
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer; Roche
 
Michael Untch
Honoraria - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Eisai Germany; Lilly; Merck Sharp & Dohme; Mundipharma; Myriad Genetics; Pfizer; Roche Pharma AG; Teva
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Mundipharma (Inst); Odonate Therapeutics; Odonate Therapeutics; Pfizer (Inst); Puma Biotechnology; Roche Pharma AG (Inst)
 
Suling Joyce Lin
No Relationships to Disclose
 
Peter Savas
No Relationships to Disclose
 
Stephen B. Fox
No Relationships to Disclose
 
Serena Di Cosimo
No Relationships to Disclose
 
Antonio Llombart Cussac
No Relationships to Disclose
 
Evandro de Azambuja
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst); Servier/Pfizer (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm Group; G1 Therapeutics; HUYA Bioscience International; Immunomedics; Lilly; Menarini; MSD; Novartis; Odonate Therapeutics; Oncolytics; Periphagen; Pfizer; PharmaMar; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - Radius Health
 
Lajos Pusztai
Honoraria - Almac Diagnostics; AstraZeneca/MedImmune; Eisai; Genentech; Immunomedics; Merck; pfizer; Pieris Pharmaceuticals; Seattle Genetics/Astellas; Syndax
Consulting or Advisory Role - Athenex; H3 Biomedicine; Merck; Novartis; PierianDx; Seagen; Syndax
Speakers' Bureau - bioTheranostics
Research Funding - AstraZeneca; Genentech; Merck; Seagen
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Merck; Puma Biotechnology
Travel, Accommodations, Expenses - Merck; Roche
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics
 
Sherene Loi
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)